Protagonist Therapeutics Inc (NASDAQ:PTGX) insider David Y. Liu sold 3,500 shares of the company’s stock in a transaction on Monday, March 12th. The stock was sold at an average price of $21.29, for a total transaction of $74,515.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Protagonist Therapeutics Inc (PTGX) traded down $0.27 during trading on Tuesday, hitting $20.67. 62,406 shares of the stock traded hands, compared to its average volume of 122,638. The company has a market capitalization of $487.08, a PE ratio of -9.53 and a beta of 1.62. Protagonist Therapeutics Inc has a 52-week low of $8.00 and a 52-week high of $23.97.
Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Wednesday, March 7th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.19. The firm had revenue of $11.28 million during the quarter, compared to the consensus estimate of $8.75 million. research analysts expect that Protagonist Therapeutics Inc will post -1.3 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PTGX. Farallon Capital Management LLC bought a new position in Protagonist Therapeutics in the fourth quarter valued at $18,720,000. First Manhattan Co. increased its stake in Protagonist Therapeutics by 2,408.2% in the fourth quarter. First Manhattan Co. now owns 416,364 shares of the company’s stock valued at $8,660,000 after acquiring an additional 399,764 shares during the last quarter. BVF Inc. IL bought a new position in Protagonist Therapeutics in the fourth quarter valued at $6,118,000. AWM Investment Company Inc. bought a new position in Protagonist Therapeutics in the fourth quarter valued at $3,686,000. Finally, Jennison Associates LLC bought a new position in Protagonist Therapeutics in the fourth quarter valued at $2,080,000. 57.77% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2018/03/14/protagonist-therapeutics-inc-ptgx-insider-sells-74515-00-in-stock.html.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.